Y-mAbs Therapeutics (YMAB) Expected to Announce Quarterly Earnings on Monday

Key Points

• Y-mAbs Therapeutics is anticipated to release its Q2 2025 earnings on August 11th, with analysts estimating a loss of ($0.27) per share and revenue of $18.40 million.
• The company recently reported a negative net margin of 31.84% and a return on equity of -30.59%, with expectations of posting $-1 EPS for both the current and next fiscal years.
• Y-mAbs Therapeutics has received mixed ratings from analysts, with an average target price of $15.60 and several recent downgrades, alongside heavy institutional ownership of 70.85%.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Y-mAbs Therapeutics to post earnings of ($0.27) per share and revenue of $18.40 million for the quarter.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative net margin of 31.84% and a negative return on equity of 30.59%. On average, analysts expect Y-mAbs Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB traded down $0.01 during midday trading on Friday, hitting $8.51. 2,820,330 shares of the stock traded hands, compared to its average volume of 475,184. The firm has a market capitalization of $385.33 million, a P/E ratio of -13.30 and a beta of 0.57. Y-mAbs Therapeutics has a one year low of $3.55 and a one year high of $16.11. The firm has a 50-day moving average of $4.87 and a two-hundred day moving average of $4.93.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Y-mAbs Therapeutics stock. AQR Capital Management LLC increased its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 869.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 164,788 shares of the company's stock after purchasing an additional 147,788 shares during the quarter. AQR Capital Management LLC owned 0.36% of Y-mAbs Therapeutics worth $730,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 70.85% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on YMAB shares. Truist Financial set a $8.60 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday. Jones Trading lowered Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. Wedbush downgraded Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and set a $8.60 target price on the stock. in a research report on Tuesday. HC Wainwright cut Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their price target for the stock from $11.00 to $8.60 in a research report on Wednesday. Finally, Bank of America cut Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a research report on Tuesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of "Hold" and an average price target of $11.16.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.